Dr. Lin Römer

January 31, 2023
Business Services

Munich, 31 January 2023 – Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today …

Vertex and CRISPR Therapeutics Announce MHRA Marketing Authorisation Application Validation for CRISPR/Cas9 GeneEdited Therapy, exagamglogene autotemcel (exa-cel

January 30, 2023
Business Services

London, UK and ZUG, Switzerland, January 27, 2023 – Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics (NASDAQ: CRSP) today announced that …

BEXIMCO PHARMACEUTICALS LIMITED Half Year Results 2022-23

January 30, 2023
Business Services

Beximco Pharmaceuticals Limited (“Beximco Pharma”, “BPL” or “the Company”; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic …

Kelso Pharma announces first product launch

January 30, 2023
Business Services

30th January 2023: Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the …

Pharmacists say England is not yet unlocking potential of self-care, with 77% backing the idea of a National Self-Care Strategy

January 30, 2023
Business Services

London, 30 January 2023. Today, a new report by Sanofi, an innovative global healthcare company, calls on the Government to …

Pfizer denies purposely mutating COVID-19 virus

January 30, 2023
Medical Communications

Big Pharma company Pfizer has publicly denied allegations that it is deliberately mutating the COVID-19 virus in order to develop …

FDA suggests individual risk assessments for blood donations to secure US blood supply

January 30, 2023
Medical Communications

The FDA has announced that it is suggesting a change from the time-based deferrals for blood donation to an individual …

Researchers develop test to predict Alzheimer’s disease years before diagnosis

January 30, 2023
Medical Communications

Researchers at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN) have developed a blood test which can potentially …

Chiesi Farmaceutici hires new CEO after $1.48bn Amryst acquisition

January 30, 2023
Business Services

Chiesi Farmaceutici, a family-owned Italian pharmaceutical company, has appointed Giuseppe Accogli as group CEO. This comes after 2020’s $1.48bn acquisition …

FDA refuses to regulate CBD, calling on Congress to take charge

January 27, 2023
Medical Communications

The FDA is calling on the US Congress to work with them on a new regulatory pathway for cannabidiol (CBD). …

FDA pulls approval of COVID-19 antibody treatment due to inefficacy against variants

January 27, 2023
Medical Communications

The FDA has revoked its approval of AstraZeneca’s Evusheld due to the fact that it is not effective against more …

Ipsen reports CHMP negative review for use of palovarotene in EU

January 27, 2023
Research and Development

Ipsen, a biopharmaceutical company focused on medicines in oncology, rare diseases and neuroscience, have been denied marketing authorisation by the …

IsoChemiX develop molecules to speed up R&D process

January 27, 2023
Research and Development

UK-based pharmaceutical drug discovery company IsoChemiX is developing molecules which will have the ability to cut both the time and …

AI finds liver cancer drug candidate in only 30 days

January 26, 2023
Research and Development

With most drug discovery and development processes taking years, if not decades, a team of scientists have broken records with …

Merck’s London research hub to begin construction in April 2023

January 26, 2023
Business Services

Merck has been planning a $1.3bn, 220,000 square foot research hub in London for six years but will finally begin …

iNtRON confirms efficacy of ‘Inhalation Anthrax’-fighting drug

January 26, 2023
Medical Communications

iNtRON, a bio-new drug developing venture company, has announced the completion of an efficacy evaluation study of BAL200. It has …

Cell BioEngines announces exclusive licencing agreement for cancer cure

January 26, 2023
Medical Communications

US-based cell and gene therapy company Cell BioEngines has announced its exclusive licencing agreement with Icahn School of Medicine at …

t.bio chooses Automata as partner for automating a key aspect of its production of iPSC derived human cells

January 26, 2023
Business Services

26th January 2023, London UK – Automata, a leading robotics and automation company powering life sciences labs, today announced it …

Orbsen Therapeutics announces encouraging interim results from the NEPHSTROM proof of concept clinical study evaluating ORBCEL™ cell therapy in patients with diabetes and advanced chronic kidney disease

January 26, 2023
Business Services

26 January 2023 Galway, Ireland – Orbsen Therapeutics Limited (“Orbsen”), a global leader in stromal cell immunotherapies, today announces encouraging …

First CAR T-cell therapy recommended for routine use on the NHS in England

January 26, 2023
Business Services

26th JANUARY 2023, LONDON, UK – Gilead Sciences Ltd. and Kite, a Gilead company, today announced that the National Institute …

The Gateway to Local Adoption Series

Latest content